 Andrey Soares
Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 8 | 2025 | 217 | 2.010 |
Why?
| | Carcinoma, Transitional Cell | 8 | 2025 | 71 | 2.010 |
Why?
| | Kidney Neoplasms | 8 | 2025 | 403 | 1.750 |
Why?
| | Urinary Bladder Neoplasms | 6 | 2025 | 252 | 1.440 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2025 | 804 | 1.130 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2024 | 51 | 1.050 |
Why?
| | Thiohydantoins | 1 | 2024 | 6 | 0.920 |
Why?
| | Health Information Interoperability | 1 | 2024 | 3 | 0.900 |
Why?
| | Urologic Neoplasms | 5 | 2025 | 31 | 0.810 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2025 | 1692 | 0.790 |
Why?
| | Computer Systems | 1 | 2022 | 45 | 0.760 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 740 | 0.650 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 226 | 0.560 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2025 | 190 | 0.450 |
Why?
| | Electronic Health Records | 4 | 2025 | 1069 | 0.390 |
Why?
| | Prostatic Neoplasms | 3 | 2024 | 1043 | 0.390 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2024 | 161 | 0.380 |
Why?
| | Neoplasm Metastasis | 5 | 2025 | 658 | 0.370 |
Why?
| | Aged, 80 and over | 9 | 2025 | 7635 | 0.290 |
Why?
| | Phenylurea Compounds | 2 | 2025 | 97 | 0.280 |
Why?
| | Antibodies, Monoclonal | 2 | 2025 | 1430 | 0.270 |
Why?
| | Quinolines | 2 | 2025 | 178 | 0.270 |
Why?
| | Retrospective Studies | 13 | 2025 | 15657 | 0.260 |
Why?
| | Humans | 30 | 2025 | 137585 | 0.250 |
Why?
| | Aged | 14 | 2025 | 23961 | 0.240 |
Why?
| | Health Level Seven | 1 | 2024 | 2 | 0.230 |
Why?
| | Biological Products | 2 | 2024 | 216 | 0.220 |
Why?
| | Male | 20 | 2025 | 67762 | 0.220 |
Why?
| | Platelet Transfusion | 1 | 2024 | 67 | 0.220 |
Why?
| | Consensus | 2 | 2024 | 683 | 0.220 |
Why?
| | Latin America | 1 | 2024 | 93 | 0.210 |
Why?
| | Immunotherapy | 2 | 2025 | 641 | 0.210 |
Why?
| | Middle Aged | 14 | 2025 | 33479 | 0.210 |
Why?
| | Immunoconjugates | 1 | 2025 | 114 | 0.210 |
Why?
| | Needs Assessment | 1 | 2025 | 376 | 0.200 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 115 | 0.200 |
Why?
| | Developing Countries | 1 | 2024 | 307 | 0.190 |
Why?
| | Computers | 1 | 2022 | 70 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 194 | 0.190 |
Why?
| | Pyridines | 2 | 2025 | 506 | 0.190 |
Why?
| | Tobacco Use | 1 | 2022 | 64 | 0.180 |
Why?
| | Anilides | 1 | 2022 | 73 | 0.180 |
Why?
| | Computer Communication Networks | 1 | 2021 | 33 | 0.180 |
Why?
| | Programming Languages | 1 | 2021 | 26 | 0.180 |
Why?
| | Cost of Illness | 1 | 2024 | 308 | 0.180 |
Why?
| | Decision Support Techniques | 1 | 2025 | 421 | 0.180 |
Why?
| | Confidentiality | 1 | 2021 | 73 | 0.170 |
Why?
| | Tobacco Products | 1 | 2022 | 138 | 0.170 |
Why?
| | Information Storage and Retrieval | 1 | 2021 | 118 | 0.170 |
Why?
| | Biosensing Techniques | 1 | 2022 | 129 | 0.160 |
Why?
| | Natural Language Processing | 1 | 2021 | 95 | 0.160 |
Why?
| | Transgender Persons | 1 | 2023 | 186 | 0.160 |
Why?
| | Metformin | 1 | 2023 | 331 | 0.160 |
Why?
| | Bias | 1 | 2021 | 218 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2025 | 10811 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 214 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2025 | 786 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 445 | 0.150 |
Why?
| | Language | 1 | 2021 | 292 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2021 | 279 | 0.140 |
Why?
| | Adult | 12 | 2025 | 37929 | 0.130 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.130 |
Why?
| | Female | 16 | 2025 | 73304 | 0.130 |
Why?
| | Adenocarcinoma | 1 | 2022 | 940 | 0.110 |
Why?
| | Platinum | 2 | 2025 | 50 | 0.110 |
Why?
| | Algorithms | 1 | 2021 | 1704 | 0.100 |
Why?
| | Prognosis | 3 | 2025 | 4030 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2111 | 0.090 |
Why?
| | Survival Rate | 2 | 2025 | 1972 | 0.080 |
Why?
| | Research | 1 | 2023 | 451 | 0.080 |
Why?
| | Neoplasms | 1 | 2022 | 2671 | 0.060 |
Why?
| | Asia | 1 | 2025 | 71 | 0.060 |
Why?
| | Orchiectomy | 1 | 2024 | 71 | 0.060 |
Why?
| | Brazil | 1 | 2024 | 167 | 0.060 |
Why?
| | Europe | 1 | 2025 | 414 | 0.050 |
Why?
| | Blood Banks | 1 | 2024 | 41 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2024 | 82 | 0.050 |
Why?
| | United States | 3 | 2025 | 14841 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2023 | 63 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2024 | 226 | 0.050 |
Why?
| | Proton Pump Inhibitors | 1 | 2023 | 109 | 0.050 |
Why?
| | Dielectric Spectroscopy | 1 | 2022 | 2 | 0.050 |
Why?
| | Nephrectomy | 1 | 2023 | 169 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 124 | 0.050 |
Why?
| | Androstenes | 1 | 2022 | 18 | 0.050 |
Why?
| | Fatigue | 1 | 2024 | 329 | 0.050 |
Why?
| | Phenylthiohydantoin | 1 | 2022 | 42 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 106 | 0.050 |
Why?
| | Common Data Elements | 1 | 2021 | 14 | 0.050 |
Why?
| | Electrodes | 1 | 2022 | 114 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 1236 | 0.040 |
Why?
| | Immunoassay | 1 | 2022 | 115 | 0.040 |
Why?
| | Life Style | 1 | 2024 | 490 | 0.040 |
Why?
| | Blood Platelets | 1 | 2024 | 408 | 0.040 |
Why?
| | Radiosurgery | 1 | 2024 | 344 | 0.040 |
Why?
| | Nitriles | 1 | 2022 | 172 | 0.040 |
Why?
| | Benzamides | 1 | 2022 | 216 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 234 | 0.040 |
Why?
| | Adolescent | 3 | 2024 | 21513 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 420 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 801 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 485 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 916 | 0.040 |
Why?
| | Erythrocytes | 1 | 2024 | 700 | 0.040 |
Why?
| | Weight Loss | 1 | 2024 | 787 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2071 | 0.040 |
Why?
| | Qualitative Research | 1 | 2025 | 1386 | 0.040 |
Why?
| | Disease Progression | 1 | 2025 | 2757 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5131 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2074 | 0.030 |
Why?
| | Young Adult | 2 | 2024 | 13209 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1477 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1639 | 0.030 |
Why?
| | Communication | 1 | 2021 | 879 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1276 | 0.030 |
Why?
| | Registries | 1 | 2021 | 2035 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3284 | 0.020 |
Why?
| | Pregnancy | 1 | 2024 | 6763 | 0.020 |
Why?
| | Risk Factors | 1 | 2025 | 10388 | 0.020 |
Why?
| | Infant | 1 | 2024 | 9465 | 0.020 |
Why?
|
|
Soares's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|